Fundraising Fox
Nosis Bio
24 employees on LinkedIn · 4 known investors
Find your way into Nosis Bio
Sign up to see every warm intro you have to Nosis Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nosis Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nosis develops a platform for receptor-targeted delivery of RNA therapeutics to specific cell types, addressing a key bottleneck in RNA drug development. The company aims to reduce the cost and timeline of bringing new RNA medicines to market.
Founders & leadership
Investors · 4
AlleyCorplisted by AlleyCorpNew York · $1M – $5M
How we know: AlleyCorp's portfolio page · the VCSheet dataset · Not right? Tell us
Alley Robotics VenturesreportedCohasset · $500K – $2Mvia Abe Murray · inferred
How we know: the VCSheet dataset · Not right? Tell us
KdT VenturesreportedAustin · $500K – $3M
How we know: the VCSheet dataset · Not right? Tell us
Related companies · 4
bioBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Syneos HealthSyneos Health is a fully integrated biopharmaceutical solutions organization that provides clinical, medical affairs, and commercial services to help pharmaceutical companies accelerate market access and patient outcomes.
Syndeio BiosciencesSyndeio Biosciences is a synapse-focused biotech developing precision neurotherapeutics for neuropsychiatric, mental health, and cognitive disorders such as depression and Alzheimer's. Its proprietary Boost Platform models synapse pharmacology, and its pipeline includes NMDA receptor positive allosteric modulators (zelquistinel and apimostinel) in Phase 2 clinical trials.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Nosis Bio.
Frequently asked questions
- What does Nosis Bio do?
- Nosis develops a platform for receptor-targeted delivery of RNA therapeutics to specific cell types, addressing a key bottleneck in RNA drug development. The company aims to reduce the cost and timeline of bringing new RNA medicines to market.
- Who founded Nosis Bio?
- Nosis Bio was founded by Seth Myers.
- Who are Nosis Bio's investors?
- Nosis Bio's investors include AlleyCorp, Madrona Venture Group, Alley Robotics Ventures, KdT Ventures.